1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Detection of histologically confirmed brain tumors on MR images acquired after administration of 0.1-mmol/kg gadoteridol or 0.1-mmol/kg gadobutrol in 139 patients with 308 brain lesions subsequently confirmed at biopsy or surgery
Lesion Detection Reader 1 Reader 2 Reader 3 Gadoteridol Gadobutrol Gadoteridol Gadobutrol Gadoteridol Gadobutrol No. patients with tumors detected at MRI 133 (95.7%) 135 (97.1%) 137 (98.6%) 136 (97.8%) 136 (97.8%) 132 (95.0%) P value (95% CI of difference, %) .317 (−4.2 to 1.4) .564 (−1.7 to 3.2) .046 (0.1 to 5.7) No. tumors detected at MRI 240 (77.9%) 236 (76.6%) 269 (87.3%) 263 (85.4%) 230 (74.7%) 220 (71.4%) P value (95% CI of difference, %) 0.480 (−2.3 to 4.9) 0.239 (−1.3 to 5.2) 0.018 (0.6 to 5.9)